NCT04563208View on ClinicalTrials.gov

Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Covid19SARS-CoV Infection
Interventions
DRUG

Placebo

Placebo administered on Days 1-5

DRUG

DuACT

Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID

Trial Locations (1)

Unknown

Sunnyside Office Park, Johannesburg

All Listed Sponsors
collaborator

SynaVir

INDUSTRY

lead

University of Witwatersrand, South Africa

OTHER

NCT04563208 - Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19 | Biotech Hunter | Biotech Hunter